Terumo (OTCMKTS:TRUMY – Get Free Report) is projected to release its results after the market closes on Thursday, November 12th. Analysts expect Terumo to announce earnings of ($0.0085) per share and revenue of $1.94 billion for the quarter.
Terumo (OTCMKTS:TRUMY – Get Free Report) last issued its earnings results on Friday, August 7th. The company reported $0.30 EPS for the quarter, beating analysts’ consensus estimates of $0.17 by $0.13. The business had revenue of $1.97 billion during the quarter, compared to analysts’ expectations of $1.84 billion. Terumo had a net margin of 13.83% and a return on equity of 10.44%. On average, analysts expect Terumo to post $0.86 EPS for the current fiscal year and $0.80 EPS for the next fiscal year.
Terumo Stock Performance
TRUMY opened at $16.16 on Tuesday. Terumo has a twelve month low of $12.08 and a twelve month high of $16.99. The firm has a market capitalization of $23.84 billion, a PE ratio of 21.21 and a beta of 0.82. The company has a current ratio of 2.19, a quick ratio of 1.37 and a debt-to-equity ratio of 0.13. The firm’s 50-day moving average price is $14.83 and its 200 day moving average price is $14.06.
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on TRUMY shares. Zacks Research raised shares of Terumo from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 13th. Nomura raised shares of Terumo from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Two investment analysts have rated the stock with a Strong Buy rating. Based on data from MarketBeat.com, the stock has an average rating of “Strong Buy”.
View Our Latest Report on Terumo
About Terumo
Terumo Corporation is a Japan-based medical technology company that develops and manufactures products for hospitals, clinics and other healthcare providers. Founded in 1921, the company began by producing clinical thermometers and has since expanded into a broad range of medical devices and services.
Terumo’s businesses include cardiovascular and vascular products, such as catheter-based devices and systems used in the treatment of heart and vascular conditions; medical care products, including infusion and injection devices; and blood and cell technologies used to collect, process and manage blood and cellular therapies.
Headquartered in Tokyo, Terumo serves healthcare customers in Japan and markets around the world.
Featured Stories
- Five stocks we like better than Terumo
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Terumo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terumo and related companies with MarketBeat.com's FREE daily email newsletter.
